Akebia Therapeutics - AKBA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.75
  • Forecasted Upside: 173.95%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.64
▼ -0.05 (-7.26%)

This chart shows the closing price for AKBA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akebia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKBA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKBA

Analyst Price Target is $1.75
▲ +173.95% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $1.75, with a high forecast of $2.00 and a low forecast of $1.25. The average price target represents a 173.95% upside from the last price of $0.64.

This chart shows the closing price for AKBA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Akebia Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2023HC WainwrightReiterated RatingNeutral$1.25Low
2/22/2023HC WainwrightReiterated RatingNeutral$1.25Low
5/16/2022HC WainwrightLower Target$2.00 ➝ $1.25Medium
4/1/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
3/31/2022BTIG ResearchDowngradeBuy ➝ NeutralMedium
3/31/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
3/31/2022HC WainwrightDowngradeBuy ➝ Neutral$10.00 ➝ $2.00High
3/31/2022MizuhoDowngradeBuy ➝ Neutral$6.00 ➝ $2.00High
3/30/2022Piper SandlerDowngradeOverweight ➝ Neutral$8.00 ➝ $2.00High
11/11/2021HC WainwrightBoost TargetBuy$6.00 ➝ $10.00High
3/8/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00High
3/8/2021HC WainwrightLower TargetBuy$9.00 ➝ $6.00Low
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
10/26/2020HC WainwrightLower TargetBuy$10.00 ➝ $9.00High
9/4/2020Morgan StanleyLower TargetEqual Weight$12.00 ➝ $3.00High
9/4/2020BTIG ResearchLower TargetBuy$26.00 ➝ $6.00Medium
9/4/2020HC WainwrightLower TargetBuy$17.00 ➝ $10.00Medium
9/4/2020MizuhoLower TargetBuy$17.00 ➝ $6.00Medium
9/3/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
8/11/2020Needham & Company LLCInitiated CoverageBuy$18.00High
8/11/2020MizuhoReiterated RatingBuy$17.00High
7/15/2020Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00Medium
7/15/2020HC WainwrightReiterated RatingBuyHigh
6/29/2020Needham & Company LLCInitiated CoverageBuy$18.00High
5/6/2020Royal Bank of CanadaBoost TargetPositive ➝ Sector Perform$8.00 ➝ $12.00Low
5/6/2020Morgan StanleyBoost TargetEqual Weight$9.00 ➝ $11.00Low
5/6/2020JPMorgan Chase & Co.Boost TargetOverweight$13.00 ➝ $18.00Low
5/6/2020MizuhoBoost TargetBuy$15.00 ➝ $17.00Medium
5/6/2020HC WainwrightBoost TargetBuy$16.00 ➝ $17.00Medium
5/5/2020Needham & Company LLCBoost TargetBuy$15.00 ➝ $18.00High
3/19/2020MizuhoReiterated RatingBuy$15.00High
3/11/2020MizuhoLower TargetBuy$16.00 ➝ $15.00High
3/10/2020Needham & Company LLCReiterated RatingBuy$15.00High
2/20/2020JPMorgan Chase & Co.Boost TargetOverweight$10.00 ➝ $13.00High
2/19/2020HC WainwrightReiterated RatingBuy$16.00High
11/19/2019MizuhoReiterated RatingBuy$16.00Medium
11/14/2019Needham & Company LLCLower TargetBuy$18.00 ➝ $15.00Medium
9/9/2019HC WainwrightReiterated RatingBuy$17.00High
8/9/2019MizuhoSet TargetBuy$16.00N/A
8/6/2019HC WainwrightLower TargetBuy ➝ Buy$19.00 ➝ $17.00High
7/11/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $21.00Medium
5/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$12.00High
3/20/2019CitigroupInitiated CoverageNeutral ➝ Neutral$9.00High
12/4/2018MizuhoReiterated RatingBuy$17.00Medium
9/7/2018Morgan StanleyInitiated CoverageEqual ➝ Equal WeightHigh
9/7/2018Morgan StanleySet TargetEqual Weight ➝ Hold$9.00Low
8/13/2018Raymond JamesInitiated CoverageBuy$18.00Medium
8/10/2018Needham & Company LLCLower TargetBuy$20.00 ➝ $18.00Medium
8/9/2018Royal Bank of CanadaReiterated RatingHold$13.00Medium
6/29/2018HC WainwrightReiterated RatingBuyHigh
6/6/2018HC WainwrightLower TargetBuy$24.00 ➝ $22.00High
5/10/2018MizuhoReiterated RatingBuy$24.00Low
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2023
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2023

Current Sentiment

  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Akebia Therapeutics logo
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $0.64
Low: $0.61
High: $0.69

50 Day Range

MA: $0.80
Low: $0.60
High: $1.15

52 Week Range

Now: $0.64
Low: $0.24
High: $2.60

Volume

1,235,641 shs

Average Volume

2,285,513 shs

Market Capitalization

$117.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Akebia Therapeutics?

The following Wall Street analysts have issued research reports on Akebia Therapeutics in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, Mizuho, Needham & Company LLC, Piper Sandler, and StockNews.com.
View the latest analyst ratings for AKBA.

What is the current price target for Akebia Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Akebia Therapeutics in the last year. Their average twelve-month price target is $1.75, suggesting a possible upside of 174.0%. Mizuho has the highest price target set, predicting AKBA will reach $2.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.25 for Akebia Therapeutics in the next year.
View the latest price targets for AKBA.

What is the current consensus analyst rating for Akebia Therapeutics?

Akebia Therapeutics currently has 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AKBA, but not buy more shares or sell existing shares.
View the latest ratings for AKBA.

What other companies compete with Akebia Therapeutics?

How do I contact Akebia Therapeutics' investor relations team?

Akebia Therapeutics' physical mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 871-2098 and its investor relations email address is [email protected] The official website for Akebia Therapeutics is www.akebia.com. Learn More about contacing Akebia Therapeutics investor relations.